(Q35070832)

6 August 2017

title

Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model (English)

1 reference

6 August 2017

0 references

11

Amy C Justice

1 reference

6 August 2017

R Scott Braithwaite

1

1 reference

6 August 2017

Mark S Roberts

2

1 reference

6 August 2017

Chung Chou H Chang

3

1 reference

6 August 2017

Matthew Bidwell Goetz

4

1 reference

6 August 2017

Cynthia L Gibert

5

1 reference

6 August 2017

Maria C Rodriguez-Barradas

6

1 reference

6 August 2017

Steven Shechter

7

1 reference

6 August 2017

Andrew Schaefer

8

1 reference

6 August 2017

Kimberly Nucifora

9

1 reference

6 August 2017

Robert Koppenhaver

10

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Annals of Internal Medicine

6 August 2017

published in

1 reference

6 August 2017

volume

148

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

178-185

1 reference

Quantifying the decrement in utility from perceived side effects of combination antiretroviral therapies in patients with HIV.

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

CD4+ count-guided interruption of antiretroviral treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Veterans Aging Cohort Study (VACS): Overview and description

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Estimating the proportion of patients infected with HIV who will die of comorbid diseases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

The case for earlier treatment of HIV infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

One thousand health-related quality-of-life estimates

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Development and verification of a "virtual" cohort using the National VA Health Information System.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Combination antiretroviral therapy and the risk of myocardial infarction

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

When To Start Therapy for HIV Infection: A Swinging Pendulum in Search of Data

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

Time to hit HIV, early and hard.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3124094

When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies

27 September 2018

1 reference

12 December 2020

Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata

1 reference

12 December 2020

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

1 reference

12 December 2020

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

1 reference

12 December 2020

Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection

1 reference

12 December 2020

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

1 reference

12 December 2020

Estimating the rate of accumulating drug resistance mutations in the HIV genome

1 reference

12 December 2020

10.7326/0003-4819-148-3-200802050-00004

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference